Combined Medication of Lovastatin with Rolipram Suppresses Severity of Experimental Autoimmune Encephalomyelitis

Ajaib S Paintlia[#], **Manjeet K Paintlia**[#], **Inderjit Singh**, and **Avtar K Singh**[*]

Darby Children's Research Institute, Pediatrics, Department of Pathology and Laboratory Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center*, Charleston, South Carolina 29425*

Abstract

Combinations of new medications or existing therapies are gaining momentum over monotherapy to treat central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS). Recent studies established that statins (HMG-CoA reductase inhibitors) are effective in experimental autoimmune encephalomyelitis (EAE), an MS model and are promising candidates for future MS medication. Another drug, rolipram (phosphodiesterase-4 inhibitor) ameliorates the clinical severity of EAE via induction of various anti-inflammatory and neuroprotective activities. In this study, we tested whether combining the suboptimal doses of these drugs can suppress the severity of EAE. Prophylactic studies revealed that combined treatment with suboptimal doses of statins perform better than their individually administered optimal doses in EAE as evidenced by delayed clinical scores, reduced disease severity, and rapid recovery. Importantly, combination therapy suppressed the progression of disease in an established EAE case via attenuation of inflammation, axonal loss and demyelination. Combination treatment attenuated inflammatory T_H1 and T_H17 immune responses and induced T_H2-biased immunity in the peripheral and CNS as revealed by serological, quantitative, and immunosorbant assay-based analyses. Moreover, the expansion of T regulatory (CD25$^+$/Foxp3$^+$) cells and self-immune tolerance was apparent in the CNS. These effects of combined drugs were reduced or minimal with either drug alone in this setting. In conclusion, our findings demonstrate that the combination of these drugs suppresses EAE severity and provides neuroprotection thereby suggesting that this pharmacological approach could be a better future therapeutic strategy to treat MS patients.

Keywords

Combination therapy; EAE; Lovastatin; Rolipram; Inflammation; Demyelination; Neuroprotection

INTRODUCTION

Experimental autoimmune encephalomyelitis (EAE) is an experimentally induced inflammatory CNS demyelinating disease that mimics many aspects of multiple sclerosis (MS)

Address for correspondence: Avtar K Singh, MD or Ajaib S Paintlia, PhD; Medical University of South Carolina, Department of Pediatrics, 173 Ashley Avenue, Charleston, SC 29425; Tel # (843) 7927542; Fax # (843) 7927130, Email: singhi@musc.edu and paintlia@musc.edu.
[#]These authors contributed equally to this study.

(Lublin, 1985). Pathophysiology of the disease includes breaching of the blood-brain barrier (BBB), infiltration of inflammatory cells (i.e., myelin reactive $CD4^+$ and $CD8^+$ T cells, and monocytes) into the CNS which perpetuate inflammatory response via activation of resident glial cells and secretion of inflammatory mediators (Hafler, 2004). These events subsequently lead to axonal loss and demyelination through multiple effector mechanisms leading to neurological deficits in MS patients.

Various immunomodulatory agents attenuate EAE with different mechanisms of action are being tested for MS treatment because presently approved MS therapies are only partially effective and are associated with side effects and potential toxicities. For instance, interferon beta (IFN-β) and glatiramer acetate (GA) were promising in some patients, but many individuals experienced poor responses or adverse effects (Arbizu, *et al.*, 2000, Dhib-Jalbut, *et al.*, 2002). Because of the inherent complexity of MS and the involvement of multiple cell types such as brain, endothelial, and vascular immune cells, the challenge of monotherapy with either pre-existing or new MS drugs is limiting the chronic progressive disability observed in affected individuals. One approach to improve treatment is to develop more efficacious agents and another, more plausible, approach is to investigate possible combinations of existing or novel agents that together synergistically or additively attenuate the disease process in different cell types.

In addition to their cholesterol-lowering effects, statins (HMG-CoA reductase inhibitors) are reported to have immunomodulatory effects that can be exploited in the treatment of CNS demyelinating diseases including MS (Paintlia, *et al.*, 2004, Youssef, *et al.*, 2002). Promising results were obtained in an initial clinical trial of simvastatin in MS (Vollmer, *et al.*, 2004) and rheumatoid arthritis (Leung, *et al.*, 2003) patients. The immnomodulatory effect of statins include preservation of BBB integrity (Stanislaus, *et al.*, 2001), inhibition of inflammatory cell infiltration into the CNS (Stanislaus, *et al.*, 2001) and skewing of T_H1 to T_H2 immune responses (Paintlia, *et al.*, 2004, Youssef, *et al.*, 2002). Recent observations of statin-mediated protection of neuroprogenitor cells from inflammatory insult and resulting enhanced myelin repair in ameliorating EAE animals suggest that, in addition to immunomodulatory activity, statins mediate neuroprotection and possibly neuroregeneration (Paintlia, *et al.*, 2005). Similarly, the selective inhibition of phosphodiesterase (PDE)-4 with rolipram, which increases intracellular cAMP, is reported to halt the induction of EAE (Genain, *et al.*, 1995, Sommer, *et al.*, 1995) via immunomodulation of the T_H1 to T_H2 immune responses (Bielekova, *et al.*, 2000). Because the cellular targets of both statins and rolipram differ with respect to their immunomodulatory activities, we hypothesized that combination therapy with suboptimal doses of these drugs could be used to attenuate EAE severity. Thus, in this study, we documented the testing of the therapeutic efficacy of suboptimal doses of these drugs in combination in an EAE model.

MATERIALS AND METHODS

Reagents

Myelin basic protein (MBP) ~50% pure from guinea pig brain, complete Freund's adjuvant (CFA), HRP-tagged anti-mouse IgG antibodies, pertussis toxin, and other chemicals were purchased from Sigma (St. Louis, MO). Lovastatin, rolipram (±; racemate), and PDE-4 inhibitor [PDI-4; 3, 5-Dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester] were purchased from Calbiochem (San Diego, CA). 'TRIZOL' reagent was purchased from Invitrogen (Carlsbad, CA). Anti- Indole-amine-2, 3-dioxygenase (IDO), -CD25 and -IgG Texas Red antibodies were purchased from Abcam Inc. (Cambridge, MA). Anti-iNOS polyclonal antibodies were purchased from Upstate (Charlottesville, VA).

Animals

Female Lewis rats (Harlan Laboratory, Harlan, IN) weighing 225–250 g were housed in the animal care facility of the Medical University of South Carolina (MUSC), throughout the experiment and provided with food and water *ad libitum*. All experiments were performed according to the National Institutes of Health *Guidelines for the Care and Use of Laboratory Animals* (NIH publication number 80-23, revised 1985) and were approved by the MUSC Animal Care and Use Committee.

EAE Induction and clinical evaluation

The procedure used for the induction of EAE has been described previously (Paintlia, *et al.*, 2004). In brief, female rats received a subcutaneous injection in the hind limb of MBP (50 μg) in 0.1 ml of phosphate-buffered saline (PBS; pH 7.4) emulsified in an equal volume of CFA supplemented with 2 mg/ml of mycobacterium tuberculosis H37Ra (Difco, Detroit, MI) on days 0 and 7. Immediately thereafter and again 24 h later, rats received pertussis toxin (200 ng, intraperitoneally, ip) in 0.1 ml of PBS. Individual rats were observed daily and clinical scores were assessed by an experimentally blinded investigator using a 0 to 5 scale: 0, no clinical score; 1, piloerection; 2, loss in tail tonicity; 3, hind leg paralysis; 4, paraplegia, and 5, moribund or dead.

Lovastatin and rolipram treatments

Lovastatin (4 mg/ml) was dissolved in 0.8% of ethanol/0.6 N NaOH and adjusted to pH 7.4 and rolipram (2 mg/ml) was dissolved initially in 100 μl of DMSO and finally suspended in PBS (pH 7.4). Different doses of lovastatin (2 and 5 mg/kg, ip) and rolipram (2, 5, and 7.5 mg/kg, sc) were administered daily starting from the day of immunization in separate groups to determine their protective optimal doses to blunt EAE. For combination treatments, suboptimal doses of both drugs i.e., lovastatin (1 mg/kg) and rolipram (1 mg/kg) were administered daily and every other day, respectively. Control EAE rats received an injection of vehicle (placebo, 0.8% ethanol in PBS, ip), daily. Drug treatment with suboptimal doses of lovastatin and rolipram in combination or separately was started either on the day of immunization or 10th days of postimmunization (dpi; animal with clinical score [CS] ≥2.0) and continued throughout the study. Corresponding control rats received an emulsion of CFA/PBS into their hind limb foot pads and a daily injection of vehicle (ip) or lovastatin (1 mg/kg) and rolipram (1 mg/kg) as described above as a drug control. Rats were sacrificed on the peak day of the disease (15th day post immunization, dpi) to collect sera and spinal cords (SC, lumbar region). Rats that developed severe EAE (CS; >4.5) in drug- or placebo-treated groups were euthanized on the same day as per the animal protocol approved by the animal care and use committee. Nine rats per treatment group were used in each experiment for analysis.

Neuropathological Evaluations

Because the most significant histopathological changes in animals with EAE are detected in the lumbar region of the SC (Eng, *et al.*, 1989), this portion of the SC was removed for analysis. At the time of sacrifice, the rats were anesthetized with pentobarbital (65 mg/kg, ip) and perfused transcardially with 4% ice-cold paraformaldehyde in 0.1 M phosphate buffer (pH 7.2). The SC was removed from the column, cut to collect the lumbar region and then paraffin-embedded. Transverse sections (5 μm) were cut and four consecutive slices were placed on the same glass slide. A series of sections was stained with hematoxylin and eosin (H&E), Luxol Fast Blue (LFB) and Bielschowsky silver to detect inflammatory infiltrates, demyelination, and axonal loss, respectively. Neuropathological data were quantified on 6–8 sections per rat. Sections were mounted with Vectashield, a aqueous mounting media (Vector Labs, Burlingame, CA), examined under a light microscope (Olympus BX-60, Goleta, CA) and images were captured with an Olympus digital video camera (Optronics; Goleta, CA) using a

dual band pass filter using Adobe Photoshop 7 software. The number of perivascular inflammatory infiltrates was calculated and expressed as the number of inflammatory infiltrates per section. Histological scores of the degree of demyelination and axonal loss of each rat were evaluated by two investigators blinded to the treatment, using a semi-quantitative system described in the literature (Giuliani, *et al*., 2005). Briefly, a score of zero indicates no disease; grade 1 refers to foci of demyelination/axonal loss, which is superficial and involves less than 25% of the lateral columns; grade 2 denotes deep foci that involve over 25% of the lateral columns; and grade 3 denotes diffuse and widespread demyelination/axonal loss.

Immunohistochemistry

For the immunohistochemistry analysis, sections were blocked with a serum-PBS solution and incubated with overnight at 4 °C with the primary antibody at the optimized working dilution prepared in PBS 0.1 M (pH 7.4) with triton (0.3%) and bovine serum albumin (BSA, 5 mg/ml). On the second day, the sections were incubated for 1 h with the secondary antibody (anti-IgG conjugated with Texas red) prepared in PBS 0.1 M plus BSA (1 mg/ml). Sections were also incubated with Texas red-conjugated IgM without primary antibody as negative controls and an appropriate mouse IgG and rabbit polyclonal IgG were used as isotype controls. After thorough washings, slides were mounted with aqueous mounting media and analyzed by immunofluorescence microscopy and images were captured by using Olympus digital camera as described above.

RNA extraction, cDNA synthesis and quantitative real time-PCR (*QRT*-PCR) analysis

Lumbar SC tissues were carefully processed for RNA isolation using 'TRIZOL' reagent according to the manufacturer's protocol as described previously (Paintlia, *et al*., 2004). Single-stranded cDNA was synthesized from SC tissue RNA from each group of animals using a superscript pre-amplification system for first-strand cDNA synthesis (BIO-RAD Laboratories, Hercules CA). *QRT*-PCR was performed using the BIO-RAD Laboratories iCycler iQ Real-Time PCR Detection System. Primers for target genes (Table 1) were designed using Primer quest software available free at website www.idtdna.com and synthesized from integrated DNA technologies (IDT, Coralville, IA). For ORT-PCR reaction supermix (IQ^{TM} SYBR Green) was purchased from BIO-RAD (BIO-RAD Laboratories, Hercules CA). Thermal cycling conditions were as follows: activation of iTaq^{TM} DNA polymerase at 95 °C for 10 min, followed by 40 cycles of amplification at 95 °C for 30 s and 58–60 °C for 1 min. The detection threshold was set above the mean baseline fluorescence determined by the first 20 cycles. Amplification reactions in which the fluorescence increased above the threshold were defined as positive. A standard curve for each template was generated using a serial dilution of the template (cDNA). Specificity of assay was determined by melting-curve analysis in each experimental run of *QRT*-PCR. The quantities of target gene expression were normalized to the corresponding GAPDH or 18S rRNA expression in test samples and data is presented as arbitrary units (au) in Tables 2 and 3)

Enzyme–linked immunosorbant assay (ELISA)

Anti-MBP specific IgG isotypes were detected in serum samples by solid phase ELISA. Briefly, plates were coated with MBP (2 μg/ml) diluted in PBS overnight in a humidified chamber followed by washing with PBS containing 0.05% Tween 20 and blocking for 1 h with 1% BSA in PBS before the addition of serum samples. Samples were diluted 1:100 in PBS following 2 h incubation at RT and then plates were washed with PBS containing 0.05% Tween 20 to remove any unbound primary antibody. Bound antibody was detected by incubation with alkaline phosphatase-labeled rat anti-mouse IgG1, anti-mouse IgG2a and anti-mouse IgG2b (1:2,000) from Serotec (Raleigh, NC) using *p*-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO) in 0.1 M glycine buffer as a substrate. Absorbance was read at 405 nm in a

microplate spectrophotometer (Bio-Tek Instruments, Winooski, VT). SC tissue homogenates were prepared in PBS with a tissue homogenizer, Ultra-Turbax (JK Lab, Germany) and centrifuged at $12,000 \times g$ for 15 min at 4 °C to collect supernatants. Interleukin (IL)-4 and IL-10 OptEIA, ELISA kits (BD Biosciences, San Jose, CA) were used with a sandwich ELISA method (using the manufacturer's protocol) to detect their levels in SC supernatants. Similarly, IL-17, interferon (IFN)-γ and tumor growth factor (TGF)-β1 were detected in the supernatant of SC homogenate using ELISA kits purchased from Rapidbio (Rapidbio sales, West Hills, CA). Data are computed as concentration of cytokine protein/mg of SC tissue protein or serum.

Immunoblotting

SC tissues were homogenized in ice-cold lysis buffer (50 mm Tris-HCl, pH 7.4, containing 50 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10% glycerol, and protease inhibitor mixture) and sample protein concentration was determined with Bradford reagent (Bio-Rad, Hercules, CA). SDS-PAGE, Western blotting and immunoblotting were performed as described previously (Paintlia, *et al*., 2004). Autoradiographs of immunoblots were generated using enhanced chemiluminescence detection kits (Amersham Biosciences, Piscataway, NJ).

Statistical analysis

Using a student's unpaired t-test for two data points and one-way ANOVA (student-Newman-Keuls to compare all pairs of columns) for multiple data points, *p*-values were determined for clinical scores, neuropathological scores, *QRT*-PCR analysis and ELISA in triplicate from three independent experiments using GraphPad software (GraphPad Software Inc. San Diego, CA). The criterion for statistical significance was p <0.05.

RESULTS

Combination therapy with suboptimal doses of lovastatin and rolipram are complementary in EAE

We first evaluated the therapeutic efficacy of both drugs i.e., lovastatin and rolipram to determine their optimal doses for blunting the progression of EAE. Clinical signs of EAE were evident in MBP-immunized and vehicle-treated rats from the 8–9th dpi onwards, followed by acute disease resulting in 80–90% mortality (clinical score (CS) ≥4.5) by the 13–15th dpi (Fig. 1A). Remaining rats in a vehicle-treated group had CS ≥4.0 till 20th dpi (Fig. 1A) and euthanized per animal protocol guidelines. Consistent with previous reports, individually administered optimal doses of lovastatin and rolipram were ≥ 2 mg/kg (Paintlia, *et al*., 2004) and ≥5 mg/kg (Genain, *et al*., 1995), respectively, to attenuate the progression of EAE (Fig. 1A–B). Of note, the 2 mg/kg dose of rolipram, however, attenuated the progression of EAE (Fig. 1B), but a complete return to normal was delayed until the 30th dpi. Results of suboptimal doses of lovastatin (1 mg/kg) and rolipram (1 mg/kg) in combination were impressive when compared with their individual performances at optimal doses (Fig. 1A–C). Interestingly, combination treatment delayed the onset and limited the severity of EAE (CS; ≤3.0) when started from the day of immunization (0th dpi, Fig. 1C), and disease improvement was sooner (17th dpi) than with individually administered optimal doses (19th dpi) (Fig. 1A–C). Of note, the suboptimal dose of lovastatin was more effective than rolipram (mortality, 70%), when administered individually from 0th dpi (Fig. 1C). Similar to the combination of lovastatin with rolipram, another inhibitor of PDE-4 (PDI-4, 1 mg/kg) also behaved similarly when used in combination with lovastatin (1 mg/kg) in this setting (Fig. 1C), thus substantiating the significance of combining of these drugs for CNS demyelinating diseases. Similar to rolipram, PDI-4 is the potent inhibitor phosphodiesterase IV and metabolites of this compound are not toxic as mentioned in product safety data sheet. Rolipram reported to have shorter half life 1–2 hrs *in vivo* (Krause, et al., 1989), but no such information for PDI-4 is currently available. Corresponding with clinical symptoms, disease-mediated weight loss in EAE rats was inhibited

by the combination of lovastatin and rolipram (data not shown). We observed no antagonism between rolipram and lovastatin, although reports in literature suggest that certain immunomodulatory agents act antagonistically (Brod, *et al.*, 2000).

Therapeutic treatment with combination of lovastatin and rolipram improves histological outcomes and impedes neurodegeneration

Generally, MS treatment is initiated after patients have developed clinical signs or brain lesions. Therefore, it is imperative to test a therapeutic regimen which can prevent EAE induction and effectively attenuate an established case of EAE. Next, we evaluated whether combination therapy of these drugs could inhibit established EAE. Drug treatment was initiated after the onset of EAE on 10th dpi when individual rat developed a CS ≥ 2.0. Combination therapy drastically inhibited EAE development, whereas no such inhibition of EAE was observed in rats treated with lovastatin or rolipram separately with the same dose (Fig. 2A).

Blinded analysis revealed that the number of infiltrates per section in rats on peak clinical day (15th dpi) was significantly reduced in rats treated with lovastatin and rolipram combination, compared to the vehicle-treated EAE rats (Fig. 2B). This reduction in the number of infiltrating inflammatory cells was also significant with lovastatin, but not with rolipram alone, compared to vehicle-treated EAE rats (Fig. 2B). The infiltration of inflammatory cells was specifically apparent in the white matter of the lateral and dorsal funiculi of the SC of EAE rats (Fig. 2C). Next, the presence of neuroinflammation and neurodegeneration was evaluated by LFB staining. Corresponding with cellular infiltration, combination therapy with lovastatin and rolipram significantly inhibited demyelination in the white matter of the SC of EAE rats, compared with vehicle-treated ones (Fig. 2B). Corresponding with cellular infiltration, there was a significant decrease in demyelination in the SC of EAE rats treated with lovastatin, but not with rolipram alone (Fig. 2B), compared to vehicle, but these effects were not as profound as those resulting from their combination. Representative sections depicting the reduction of cellular infiltration and demyelination in the lateral funiculi of the SC by combination therapy of lovastatin and rolipram in EAE rats compared with vehicle are displayed in Fig. 2D. Demyelination observed in the SC of EAE rats was further supported by immunoblotting for myelin protein i.e., MBP. Combination treatment with lovastatin and rolipram attenuated the inflammation-mediated breakdown of the myelin sheath in the SC of EAE rats (Fig. 3A). But this reduction of myelin breakdown was partial in the SC of EAE rats treated with lovastatin or rolipram alone (Fig. 3A). Likewise, axonal loss was markedly reduced by combination treatment with lovastatin and rolipram in the SC of EAE rats, compared with vehicle (Fig. 3B). The axonal loss was however, significantly attenuated by lovastatin and rolipram alone in EAE rats, compared with vehicle, but this reduction was not as impressive as that was resulting from their combination (Fig. 3B). In addition to the quantification of axonal loss, silver impregnation of axons also revealed the improved integrity of white matter in the affected lateral funiculi of SC sections of EAE rats (Fig. 3C). Taken together these data provide evidence that combination therapy with lovastatin and rolipram attenuates CNS invasion and subsequently impedes neurodegeneration in the EAE rats.

Combination treatment of lovastatin and rolipram attenuates infiltration of mononuclear cells and improves endothelial functions

Because the observed histological changes and neurodegeneration in the MS brain are associated with the invasion of the CNS by invading cells including myelin-reactive T cells (CD4+ and CD8+) and monocytes (CD11b+) (Hafler, 2004), we next examined SC tissues for the presence of these cells using *QRT*-PCR. As expected, the transcripts for CD4, CD8, and CD11b proteins were elevated in the SC of vehicle-treated EAE rats, suggestive of CNS invasion by autoreactive T cells and monocytes (Fig. 4A–B). Conversely, combination therapy with lovastatin and rolipram significantly attenuated this invasion of CNS by autoreactive T

cells and monocytes as compared to vehicle (Fig. 4A–B). Of note, the observed effect of combination treatment with suboptimal dose of lovastatin and rolipram to attenuate the CNS invasion was better than their same doses when used separately (Fig. 4A–B).

CNS invasion is considered to be facilitated via interaction between adhesion molecules (ICAM-1 and VCAM-1) on endothelial cells and LFA-1 on leukocytes including the release of chemokines (MCP-1) and expression of their receptors (CCR2) on invading leukocytes (Dopp, *et al.*, 1994). Therefore, we next examined the expression of these mediators in the SC involved in the CNS invasion and endothelial dysfunction. Corresponding with cellular infiltration, the increased level of transcripts for ICAM-1, VCAM-1, MCP-1, and CCR2 were significantly attenuated by combination treatment with lovastatin and rolipram in the SC of EAE rats compared to vehicle (Fig. 4C–D). Of note, an increased level of MCP-1 and CCR2 transcripts in vehicle-treated EAE rats is comparable to their previously documented mRNA levels and immunohistochemistry staining data in the SC of EAE rats as reported earlier (Paintlia, *et al.*, 2004). It is noteworthy that the reduction of these mediators in the SC of EAE rats was reduced to 50% and 20% by individually administered lovastatin and rolipram, respectively, compared with vehicle, but it was not as profound as that observed with their combination (Fig. 4A–D). Together, these data suggest that the combination therapy of lovastatin and rolipram reverses EAE pathogenesis via attenuation of cellular infiltration and improvement of endothelial function in the CNS.

The combination of lovastatin and rolipram promotes a bias towards T$_H$2 immunity

Previously, we had documented that transcripts of immune cells associated with T$_H$1 immune responses were elevated in the SC of EAE rats (Paintlia, *et al.*, 2004). Recent studies revealed that an IL-23-induced subset of T cells producing IL-17 (T$_H$17) is involved in EAE progression (Kleinschek, *et al.*, 2007). Interestingly, combination treatment with lovastatin and rolipram significantly reduced transcripts for pro-inflammatory cytokines associated with EAE development i.e., IL-23, IL-17, IFN-γ, TNF-α, and IL-1β in the SC of EAE animals compared with vehicle (Fig. 5A–B). In addition, the level of transcription factor, retinoic acid orphan receptor gamma t (RORγt), involved in the expression of IL-17 by T$_H$17 cells was also reduced significantly by combination therapy compared to vehicle (Fig. 5B). ELISA-based assays further supported these observations and showed the significant reduction of IFN-γ (Fig. 6A) and IL-17 (Fig. 6B) proteins in the SC of EAE rats by combination therapy compared with vehicle. Likewise, iNOS transcripts (Fig. 5A) and protein (Fig. 6C–D) were reduced significantly in the SC of EAE rats by drug combination therapy compared to vehicle. Of note, no significant reduction of these mediators was observed in the SC of EAE rats treated with rolipram alone when compared with vehicle (Fig. 5A–B and Fig. 6A–D). Although expression of these mediators in the SC of EAE rats treated with lovastatin alone was significantly reduced when compared with vehicle, this reduction was not as profound as that observed when lovastatin was combined with rolipram (Fig. 5A–B and Fig. 6A–D).

Because T$_H$2 immunity play an important role in the suppression of autoimmune disease i.e., EAE (O'Garra, *et al.*, 1997), we next measured T$_H$2 cytokines i.e., IL-4 and IL-10 in the SC. Combination treatment with lovastatin and rolipram significantly increased IL-4 and IL-10 transcripts (Fig. 5C) and protein (Fig. 6E–F) in the SC of EAE rats compared to vehicle. These cytokines, however, were elevated significantly in the SC of lovastatin-treated EAE rats, especially IL-10 when compared with vehicle, but this was not as profound as that observed with its combination with rolipram (Fig. 5C and Fig. 6E–F). No significant change in these cytokines was observed in the SC of rolipram-treated EAE rats compared to vehicle (Fig. 5C and Fig. 6E–F).

The above data imply that combination therapy may additively modulate T-cell function *in vivo*. The reduction in SC inflammation is suggestive of its potential for selective reduction in

the T_H1 cell reactivity that primarily mediates the immune response in the periphery generally associated with EAE progression. If this is the case, a consequence of combination therapy may be a bias toward T_H2 immunity. Because the T_H1 immunity predominantly elicits IgG2a, whereas T_H2 immunity produces higher levels of IgG1 in mice (Hooper, *et al.*, 1998), we next assessed whether combination therapy influences humoral immune response to MBP in the peripheral immune system in EAE rats. Anti-MBP antibodies of the IgG2a subclass that were elevated in the sera of vehicle-treated EAE rats were significantly reduced by combination therapy of these drugs (Fig. 5E). Conversely, anti-MBP antibodies of IgG2b and IgG1 subclasses were significantly elevated in the sera of EAE rats treated with these drugs in combination, compared with vehicle (Fig. 5E). No such change was observed in the level of IgG2a in the sera of EAE rats treated with lovastatin or rolipram alone when compared with vehicle (Fig. 5E). IgG1 and IgG2b were significantly elevated in EAE rats treated with lovastatin but not in those treated with rolipram alone, compared with vehicle (Fig. 5E). Altogether, these data suggest that combination therapy of lovastatin and rolipram attenuates inflammatory T_H1 and T_H17 immune responses and causes a bias towards T_H2 immunity in the peripheral and CNS.

The combination of lovastatin and rolipram promotes expansion of T regulatory (Treg) cells and immune tolerance in the CNS

Since T regulatory (Treg) cells play an important role in the suppression and reversal of EAE (Yu, *et al.*, 2005), we next measured the level of transcripts for CD25 and its transcription factor, Forkhead box P3 (Foxp3) proteins as a marker of Treg ($CD25^+/Foxp3^+$) cells in the CNS. Combination treatment with lovastatin and rolipram markedly increased CD25 transcript (Fig. 5B) and protein (Fig. 7A) including Foxp3 transcript (Fig. 5D) in the SC of EAE rats compared to vehicle. Furthermore, TGF-β1 transcripts (Fig. 5C) and protein (Fig. 7B) were also increased significantly in the SC of EAE rats by combination therapy compared to vehicle. No change in the expression of these mediators was observed upon treatment with rolipram in the SC of EAE rats compared to vehicle except CD25 (Fig. 5B–D and Fig. 7A–B). Although, the expression of these mediators in the SC of EAE rats treated with lovastatin was significantly elevated when compared with vehicle, this change was not as dramatic as that observed when lovastatin was combined with rolipram (Fig. 5B–D and Fig. 7A–B).

The increased expression of indole-amine-2, 3-dioxygenase (IDO) in dendritic cells is important for the suppression of EAE (Kwidzinski, *et al.*, 2005) via suppression of T-cell responses and induction of immune tolerance (Mellor and Munn, 2004); thus, we next determined the status of IDO (transcript and protein) in the CNS. Combination treatment with lovastatin and rolipram significantly increased IDO transcripts in the SC of EAE rats compared with vehicle (Fig. 5D). These results were further supported by immunoblotting of IDO protein (Fig. 7A) and immunohistochemistry of transverse SC sections (Fig. 7C). IDO immunostaining was evident in the dorsal funiculi of the SC of EAE rats treated with lovastatin and rolipram in combination (Fig. 7C). The level of IDO transcripts (Fig. 5D) and protein (Fig. 7A and C) in the SC of EAE rats treated with lovastatin was significantly elevated when compared with vehicle, but it was not as impressive as that observed with the drug combination. No significant change in IDO transcripts (Fig. 5D) and protein (Fig. 7A and C) was observed in the SC of EAE rats treated with rolipram alone when compared with vehicle. Together, these data imply that combined therapy of lovastatin and rolipram also promotes Treg expansion and immune tolerance in the CNS as mechanism of protection to suppress EAE.

DISCUSSION

Several reports suggest that combination therapy with existing or novel MS therapeutics in the treatment of MS have better clinical outcomes than with monotherapy. Combination therapy

is considered to be advantageous if both drugs (a) have different mechanisms of action, (b) have excellent safety profiles, and (c) have no additional toxicities when used in combination for additive or synergistic effects (Stuve, *et al.*, 2006). In this regard, statins (Paintlia, *et al.*, 2004, Youssef, *et al.*, 2002) and rolipram (Bielekova, *et al.*, 2000, Sommer, *et al.*, 1995) meet these criteria and both characteristically prevent/ameliorate EAE. Also, both statins (Johnson-Anuna, *et al.*, 2005) and rolipram cross the BBB (Krause and Kuhne, 1988) to interfere in the neurodegenerative process in the CNS. In this study, we show that combined treatment with lovastatin and rolipram, compared to individual drug treatment, was associated with significant suppression of EAE severity via inhibition of cellular infiltration and improved endothelial function in the CNS. The attenuation of inflammatory T_H1 and T_H17 immune responses and induction of biased T_H2 immunity was apparent in the peripheral and CNS including the expansion of Treg cells and immune tolerance. Subsequently, it was associated with profound reduction of demyelination and axonal loss in the CNS.

The EAE model is useful for initial testing of potential combination therapies for MS. Combination therapies are tested in animals (Brod, *et al.*, 2000, Soos, *et al.*, 2002) and humans (Dhib-Jalbut, *et al.*, 2002, Ytterberg, *et al.*, 2007), including phase-I clinical trials (Jeffery, *et al.*, 2005, Rudick, *et al.*, 2006) with major FDA-approved immunomodulators including IFN-β and GA in the MS regimen. Moreover, other combination therapies are also being investigated in MS and EAE with FDA-approved therapies and other novel therapeutics for MS including statins and minocycline (Giuliani, *et al.*, 2005, Luccarini, *et al.*, 2008, Stuve, *et al.*, 2006). Results of a recently conducted phase 1 trial of IFN-β and atorvastatin combined therapy in MS patients are quite impressive and provide a rationale for conducting phase II/III trials (Paul, *et al.*, 2008). *In vitro* studies revealed that immunomodulatory actions of statins are comparable to IFN-β (Neuhaus, *et al.*, 2005). Considering statins to be future MS therapeutics, we previously demonstrated an immunomodulatory synergy with lovastatin and another novel therapeutic drug, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside in EAE (Paintlia, *et al.*, 2006). Overall, these studies support the notion that immunomodulatory agents with different mechanisms of action can be combined for the treatment of MS and provide a rationale for testing the combination of lovastatin plus rolipram. The present study establishes that the combining of suboptimal doses of lovastatin and rolipram provides better outcomes by impeding EAE severity and neurodegeneration than their individually administered doses. In particular, despite significant reduction of the some of the inflammatory mediators by an individually administered dose of these drugs especially lovastatin, the disease severity was not attenuated thereby suggestive of the potential benefits of combination therapy over monotherapy for treating CNS demyelinating diseases. Of note, the combined therapy with suboptimal doses of these drugs was better than their optimal individually administered doses. The observed effects of these drugs in combination are complementary to their immunomodulatory and neuroprotective activities as discussed below.

In organ-specific autoimmunity, the balance of cytokines is a key determinant of resistance or susceptibility. In EAE, disease susceptibility is thought to correlate with the expression of proinflammatory cytokines such as IL-23, IFN-γ, TNF-α, IL-6, and IL-1β including iNOS. Conversely, T_H2 cytokines such as IL-4, IL-10 and IL-13 are important for preventing or ameliorating EAE (O'Garra, *et al.*, 1997). IFN-γ producing cells can induce EAE, and their presence within the CNS likely contributes to acute inflammation, whereas the IL-17 immune pathway is suggested to play an important role in the disease process (Kleinschek, *et al.*, 2007). Inflammation is considered to be the cause of tissue damage as a result of CNS invasion by inflammatory infiltrates. Combined treatment with lovastatin and rolipram significantly attenuated the infiltration of inflammatory cells and induced a biased anti-inflammatory T_H2 immunity which attenuates peripheral and central inflammation through bystander suppression. Consistent with these findings, statins were previously shown to attenuate EAE development by promoting a T_H1 to T_H2-biased immune responses (Paintlia, *et al.*, 2004,

Youssef, *et al*., 2002). Moreover, a recent study demonstrated that statins can inhibit IL-17 transcription and secretion by human CD4[+] T cells (Zhang, *et al*., 2008). Similar to statins, rolipram has been reported to attenuate the induction of chronic EAE (Bielekova, *et al*., 2000, Genain, *et al*., 1995) via immunomodulation of T_H1 to T_H2 immune responses (Abbas, *et al*., 2000, Bielekova, *et al*., 2000). It is worth mentioning that statins act on multiple targets in EAE modulation. Statins, by inhibiting HMG-CoA reductase, play a critical role in the mevalonate pathway that regulates the synthesis of cholesterol, and they interact with isoprenoids which mediate the membrane association of many GTPases (Zhang and Casey, 1996). Depletion of isoprenoid intermediates *in vivo* by statins, promotes a T_H2 bias by reducing the membrane association of Ras and RhoA, which have an important role in extracellular signal-regulated kinases and p38 kinases (Dunn, *et al*., 2006).

An invasion of the CNS by autoreactive T cells and monocytes is facilitated by the breaching of the BBB and the expression of adhesion molecules in endothelial cells during EAE progression (Eralinna, *et al*., 1996). We and others previously documented that statins inhibit the infiltration of inflammatory cells into the CNS (Stanislaus, *et al*., 2001, Walters, *et al*., 2002, Youssef, *et al*., 2002). Detailed studies revealed that the inhibitory effects of statins on the preservation of the BBB are mediated by attenuation of isoprenylation of endothelial cell proteins such as Rho GTPAses (Walters, *et al*., 2002). In agreement with these findings, combination therapy significantly reduced transcripts for T cells, monocytes, and adhesion molecules in the SC, suggesting improved endothelial functions and attenuation of CNS invasion (please see Fig. 4). The additional mechanism by which statins inhibit inflammatory cell transmigration through the BBB is by reducing the activity of matrix metalloproteinase (MMP) such as MMP-9. Statins are reported to attenuate the expression MMP-9 in endothelial cells by the RhoA/ROCK pathway through an isoprenoid-dependent mechanism (Turner, *et al*., 2005). Likewise, rolipram treatment has been shown to stabilize the BBB in EAE animals (Folcik, *et al*., 1999). In addition, rolipram has been shown to inhibit NF-κB and MMP-9 activities in activated T cells (Sanchez, *et al*., 2005).

Recent studies revealed that Tregs (CD25[+]Foxp3[+] T regulatory) are important in maintaining self tolerance to inhibit the function of effector T cells especially during T_H17 immune responses (Yu, *et al*., 2005). TGF-β1 is key cytokine in the generation of Treg cells and a recent study revealed that its secretion by neurons is important for enhancing Treg cell expansion in the CNS to suppress EAE progression (Liu, *et al*., 2006). Consistent with our previous documentation, combination therapy of lovastatin and rolipram showed increased expression of TGF-β1 in the CNS (Paintlia, et al., 2004). A very recent study demonstrated that statin treatment promotes the generation of Treg cells in treated peripheral naïve CD4[+] T cells (Mausner-Fainberg, *et al*., 2008). Phosphodiesterase inhibitors are also reported to upregulate Treg cells in experimental autoimmune myasthenia gravis (Aricha, *et al*., 2006). Another important candidate, IDO (tryptophan metabolizing enzyme), in the dendritic cells is also reported to involved in the suppression of EAE progression (Kwidzinski, *et al*., 2005) via suppression of the proliferation of effector T cells and an induction of immune tolerance (Mellor and Munn, 2004). Combined treatment with lovastatin and rolipram significantly increased these mediators (transcripts and proteins) in the CNS of an established EAE case (Table 3, and Fig. 5). These observed effects of these drugs in combination whether resulting from the reduced inflammation by an effect on immune cells in the periphery or due to the modulation of immune cells in the CNS is needed to be ascertained. Overall, these findings suggest that the observed immunomodulatory activities of these drugs in combination are attributed in part to the induction of T_H2 biased immunity and generation of Treg cells and immune tolerance.

Local antigen presentation is a critical requirement for the initiation and perpetuation of the chronic inflammatory response within the CNS. While the CNS is devoid of professional

antigen presenting cells, MHC class II antigens and costimulatory CD80 and CD86 molecules are upregulated in microglia and macrophages in response to local cytokine production (Youssef, *et al*., 2002). CNS resident astrocytes can also upregulate MHC class II after activation by IFN-γ (Cornet, *et al*., 2000). Current studies revealed that peripherally-derived myeloid dendritic cells (mDCs) accumulate in the CNS during relapsing EAE (Bailey, *et al*., 2007), and mDCs localize in the central parts of the active lesions and induce IL-17 production by CD4 cells. This effect of T-cell differentiation mediated by mDCs in the CNS plays important role in the chronic inflammatory response. Lovastatin has been reported to inhibit the expression of TNF-α and IL-1β in microglia and astrocytes (Pahan, *et al*., 1997). Treatment of microglia with a statin attenuated IFN-γ inducible transcription of MHC class II expression (Kwak, *et al*., 2001). Likewise, rolipram has been reported to inhibit the secretion of TNF-α by macrophages and monocytes via blocking the degradation of cAMP (Torphy and Undem, 1991). In addition, rolipram has been shown to downregulate the expression of pro-inflammatory cytokine but upregulate the expression of anti-inflammatory cytokines in the CNS (Yoshikawa, *et al*., 1999). These effects of statins and rolipram on modulation of the inflammatory response in brain cells are critical for their neuroprotective activities in the CNS. In addition, statins and rolipram are reported to inhibit NMDA-induced neuronal cell death (Zacco, *et al*., 2003, Zou and Crews, 2006). Recent studies provide evidence that statins protect neuroprogenitor cells from inflammatory insult and enhance myelin repair in ameliorating EAE animals thereby suggesting that lovastatin may promote neurorepair in EAE (Lee, *et al*., 2004, Paintlia, *et al*., 2005, Paintlia, *et al*., 2008, Sim, *et al*., 2008). Likewise, PDE-4 inhibitor-mediated preservation of cAMP has been shown to protect neurons against β-amyloid-induced neurotoxicity (Echeverria, et al., 2005). In addition, cAMP has been implicated in the survival of hippocampal neurons *in vitro* under conditions of reduced energy availability during glucose deprivation and glutamate excitotoxicity (Culmsee, et al., 2001).

In conclusion, our study demonstrated for the first time that combination of lovastatin and rolipram provide better protection in EAE than either drug when used individually at suboptimal doses. The partial reduction of myelin breakdown and axonal degeneration in EAE animals treated with these drugs separately may be attributed to their partial inhibition of inflammatory response in the CNS. In addition, the consistently observed weaker effects of rolipram as a single therapy than lovastatin are in agreement with a previous report demonstrating rolipram induced strong preventive effects with limited therapeutic efficacy in EAE Lewis rats (Jung, et al., 1996). The major drawback of rolipram administration in humans could be its tendency to induce vomiting as observed in ferrets (Robichaud, et al., 2001). Importantly, it could be subjugated by an intramuscular injection of ondansetron hydrochloride dehydrate (0.3 mg/kg) 20 min prior to rolipram administration as reported earlier (Genain, et al., 1995). It is noteworthy that administration of ondansteron hydrochloride in EAE rats neither aggravates nor attenuates EAE disease associated symptoms (data not shown). Although other mechanisms may contribute to the additive/synergistic immunomodulatory activities of combined therapy of lovastatin and rolipram, as mentioned above, the observed effects of these drugs in combination are complementary. At this time, the precise mechanism and contribution of these drugs in combination in the attenuation of EAE pathogenesis is not fully understood. Overall, the combined therapy of lovastatin and rolipram is an excellent therapeutic approach for the treatment of MS. Future clinical trials are warranted to investigate the effect of these drugs in combination therapy in MS.

Acknowledgements

Abbreviations

EAE

Experimental autoimmune encephalomyelitis

MS

Multiple sclerosis

SC

spinal cord

CNS

central nervous system

dpi

Days of post-immunization

QRT-**PCR**

Quantitative real-time-polymerase chain reaction

LOV

Lovastatin

RLP

Rolipram

PDE-4

Phosphodiesterase-4

CS

Clinical score

LFB

Luxol fast blue

H & E

Hematoxlin and Eosin

IFN

Interferon

IL

Interleukin, TGF, Tumor growth factor

ICAM

Intracellular adhesion molecule

VCAM

Vascular adhesion molecule

Foxp3

Forkhead box P3

RORγt

retinoic acid orphan receptor gamma t

IDO

Indole-amine-2,3-dioxygenase

BBB

Blood brain barrier

References

1. Abbas N, Zou LP, Pelidou SH, Winblad B, Zhu J. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 2000;32:93–99. [PubMed: 11078155]

2. Arbizu T, Alvarez-Cermeno JC, Decap G, Fernandez O, Uria DF, Garcia Merino A, Izquierdo G, Montalban X. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 2000;102:209–217. [PubMed: 11071104]

3. Aricha R, Feferman T, Souroujon MC, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. Faseb J 2006;20:374–376. [PubMed: 16365386]

4. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007;8:172–180. [PubMed: 17206145]

5. Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000;164:1117–1124. [PubMed: 10623864]

6. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000;47:127–131. [PubMed: 10632113]

7. Cornet A, Bettelli E, Oukka M, Cambouris C, Avellana-Adalid V, Kosmatopoulos K, Liblau RS. Role of astrocytes in antigen presentation and naive T-cell activation. J Neuroimmunol 2000;106:69–77. [PubMed: 10814784]

8. Culmsee C, Monnig J, Kemp BE, Mattson MP. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 2001;17:45–58. [PubMed: 11665862]

9. Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002;8:485–491. [PubMed: 12474988]

10. Dopp JM, Breneman SM, Olschowka JA. Expression of ICAM-1, VCAM-1, L-selectin, and leukosialin in the mouse central nervous system during the induction and remission stages of experimental allergic encephalomyelitis. J Neuroimmunol 1994;54:129–144. [PubMed: 7523443]

11. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006;203:401–412. [PubMed: 16476765]

12. Echeverria V, Clerman A, Dore S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci 2005;22:2199–2206. [PubMed: 16262658]

13. Eng LF, D'Amelio FE, Smith ME. Dissociation of GFAP intermediate filaments in EAE: observations in the lumbar spinal cord. Glia 1989;2:308–317. [PubMed: 2530171]

14. Eralinna JP, Soilu-Hanninen M, Roytta M, Hukkanen V, Salmi AA, Salonen R. Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. J Neuroimmunol 1996;66:103–114. [PubMed: 8964903]

15. Folcik VA, Smith T, O'Bryant S, Kawczak JA, Zhu B, Sakurai H, Kajiwara A, Staddon JM, Glabinski A, Chernosky AL, Tani M, Johnson JM, Tuohy VK, Rubin LL, Ransohoff RM. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J Neuroimmunol 1999;97:119–128. [PubMed: 10408965]

16. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J, Hauser SL. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci U S A 1995;92:3601–3605. [PubMed: 7536938]

17. Giuliani F, Fu SA, Metz LM, Yong VW. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 2005;165:83–91. [PubMed: 15958276]

18. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788–794. [PubMed: 15067307]

19. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 1998;72:3711–3719. [PubMed: 9557653]

20. Jeffery DR, Chepuri N, Durden D, Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005;11:296–301. [PubMed: 15957510]

21. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Muller WE, Wood WG. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005;312:786–793. [PubMed: 15358814]

22. Jung S, Zielasek J, Kollner G, Donhauser T, Toyka K, Hartung HP. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996;68:1–11. [PubMed: 8784254]

23. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, Blumenschein WM, McClanahan T, Brombacher F, Hurst SD, Kastelein RA, Cua DJ. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007;204:161–170. [PubMed: 17200411]

24. Krause W, Kuhne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988;18:561–571. [PubMed: 3400274]

25. Krause W, Kuhne G, Matthes H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 1989;19:683–692. [PubMed: 2669364]

26. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001;131:41–46. [PubMed: 11219190]

27. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J 2005;19:1347–1349. [PubMed: 15939737]

28. Lee OK, Ko YC, Kuo TK, Chou SH, Li HJ, Chen WM, Chen TH, Su Y. Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. J Cell Biochem 2004;93:917–928. [PubMed: 15389871]

29. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524–1530. [PubMed: 12538717]

30. Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006;12:518–525. [PubMed: 16633347]

31. Lublin FD. Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis. Springer Semin Immunopathol 1985;8:197–208. [PubMed: 3931271]

32. Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi MC, Grossi C, Massacesi L, Casamenti F. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 2008;211:214–226. [PubMed: 18346732]

33. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, George J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197:829–839. [PubMed: 17826781]

34. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762–774. [PubMed: 15459668]

35. Neuhaus O, Stuve O, Archelos JJ, Hartung HP. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate. J Neurol Sci 2005;233:173–177. [PubMed: 15949504]

36. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997;9:872–883. [PubMed: 9492992]

37. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671–2679. [PubMed: 9389730]

38. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb J 2005;19:1407–1421. [PubMed: 16126908]

39. Paintlia AS, Paintlia MK, Singh AK, Singh I. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 2008;73:1381–1393. [PubMed: 18239032]

40. Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, Singh I. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 2004;77:63–81. [PubMed: 15197739]

41. Paintlia AS, Paintlia MK, Singh I, Singh AK. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 2006;169:1012–1025. [PubMed: 16936274]

42. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008;3:e1928. [PubMed: 18398457]

43. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001;40:262–269. [PubMed: 11114405]

44. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911–923. [PubMed: 16510745]

45. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;168:13–20. [PubMed: 16182379]

46. Sim FJ, Lang JK, Ali TA, Roy NS, Vates GE, Pilcher WH, Goldman SA. Statin treatment of adult human glial progenitors induces PPARgamma-mediated oligodendrocytic differentiation. Glia 2008;56:954–962. [PubMed: 18383345]

47. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995;1:244–248. [PubMed: 7585041]

48. Soos JM, Stuve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol 2002;169:2231–2235. [PubMed: 12193686]

49. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001;66:155–162. [PubMed: 11592110]

50. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006;116:1037–1044. [PubMed: 16543951]

51. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991;46:512–523. [PubMed: 1877039]

52. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Faseb J 2005;19:804–806. [PubMed: 15728660]

53. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607–1608. [PubMed: 15145635]

54. Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment

to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol 2002;168:4087–4094. [PubMed: 11937568]

55. Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler 1999;5:126–133. [PubMed: 10335522]

56. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78–84. [PubMed: 12422218]

57. Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist LW, von Koch L. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand 2007;116:96–99. [PubMed: 17661794]

58. Yu P, Gregg RK, Bell JJ, Ellis JS, Divekar R, Lee HH, Jain R, Waldner H, Hardaway JC, Collins M, Kuchroo VK, Zaghouani H. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 2005;174:6772–6780. [PubMed: 15905518]

59. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003;23:11104–11111. [PubMed: 14657168]

60. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241–269. [PubMed: 8811180]

61. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008;180:6988–6996. [PubMed: 18453621]

62. Zou J, Crews F. CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death. Cell Mol Neurobiol 2006;26:385–405. [PubMed: 16633891]

Figure 1. Combination therapy with suboptimal doses of lovastatin and rolipram are complementary in EAE

EAE was induced in female Lewis rats using guinea pig MBP antigen emulsified in CFA and treatment with lovastatin (LOV) and rolipram (RLP) in combination or individually was performed as described under Materials and Methods. Drug treatments were started from the day of immunization of rats with MBP and continued until the end of the study. (**A**) Plot depicts clinical score associated with EAE in treated/untreated rats with different doses of LOV. (**B**) Plot depicts clinical score associated with EAE in treated/untreated rats with different doses of RLP. (**C**) Plot depicts clinical score associated with EAE in treated/untreated rats with suboptimal doses of LOV and RLP in combination and individually including PDEI-4 (another

inhibitor of phosphodiesterase-4). Vehicle (VEH)- and LOV plus RLP-treated rats immunized with CFA emulsion without MBP were referred to as CON (VEH) and CON (LOV + RLP), respectively. Data in plots are presented as Mean ± SD of 9 rats treated similarly in a group. Statistical significance indicated as ** p<0.01 and *** p<0.001 versus EAE (VEH).

Figure 2. Combined treatment of lovastatin and rolipram attenuates cellular infiltration and demyelination in the SC of EAE rats

Treatment with lovastatin (LOV; 1 mg/kg) and rolipram (RLP; 1 mg/kg) in combination or individually was commenced in rats after the establishment of EAE (clinical score ≥2.0) as described under methods. Plot depicts clinical score in EAE animals treated with LOV and RLP in combination or individually (A). Plot depicts cellular infiltration and demyelination in the SC of EAE rats treated with LOV and RLP in combination or individually (B). Representative photograph of the lateral funiculus of SC stained with H&E (C) and both H&E and LFB (D) from each group of rats i.e., a) CON (VEH), b) CON (LOV + RLP), c) EAE (VEH), d) EAE (RLP), e) EAE (LOV) and f) EAE (LOV + RLP) demonstrates existing cellular

infiltration and demyelination. Yellow arrowhead depicts cellular infiltration in the white mater and V indicates 'vessel' (C). Data in plots are expressed as Mean ± SD from three independent experiments (A) and histological images of SC (n = 9)/group (B). Statistical significance * p<0.05, ** p<0.01 and *** p<0.001 versus EAE (VEH).

Figure 3. Attenuation of axonal loss and demyelination in the SC of EAE rats by combination therapy of lovastatin and rolipram

Treatment with lovastatin (LOV; 1 mg/kg)) and rolipram (RLP; 1 mg/kg) in combination or individually was commenced in rats after the establishment of EAE (clinical score ≥2.0) as described under Methods. Autoradiograph of immunoblotting depicts level of MBP isoforms in the SC of treated/untreated control and EAE animals (**A**). Plot depicts histological score of axonal loss in the white matter of lateral funiculi of SC of EAE rats treated with drugs in combination or individually or with vehicle (VEH) only (**B**). Representative photograph of the lateral funiculus of SC demonstrate impregnation of axons by Beilschowsky's silver staining (**C**). Labeling of micrographs indicates a) CON (VEH), b) CON (LOV + RLP), c) EAE (VEH),

d) EAE (RLP), e) EAE (LOV) and f) EAE (LOV + RLP) in both B and D. Data in plot is presented as Mean ± SD from three independent experiments with 9 rats/group and histological images of SC (n = 9)/group. Statistical significance * $p<0.05$, ** $p<0.01$ and *** $p<0.001$ versus EAE (VEH).

Figure 4. Expression of transcripts for inflammatory infiltrates, adhesion molecules and chemokines including receptors in the SC of EAE rats treated with lovastatin and rolipram in combination or individually

Plots depict the level of transcripts A; CD4 and CD8 T cells, B; CD11b monocytes, C; ICAM-1 and VCAM-1, and D; MCP-1 and CCR-2 in the SC of EAE (n = 9) and control (n = 6) rats treated with lovastatin (LOV) and rolipram (RLP) in combination or individually as determined by *QRT*-PCR as described under methods. Data in plots are expressed as Mean ± SD from three independent experiments. Statistical significance * p<0.05, ** p<0.01, *** p<0.001 and 'NS' (not-significant) versus EAE (VEH).

Figure 5. Level of transcripts for pro-inflammatory and anti-inflammatory mediators in the SC and anti-MBP immunoglobulin isotypes in the serum of EAE rats treated with lovastatin and rolipram in combination or individually

Plots depict the level of transcripts A; IFN-γ, TNF-α, IL-1β and iNOS, B; IL-23, IL-17, RORγt and CD25, C; IL-4, IL-10 and TGF-β1, and D; Foxp3 and IDO in the SC of EAE (n = 9) and control (n = 6) rats treated with lovastatin (LOV) and rolipram (RLP) in combination or individually as determined by *QRT*-PCR as described under methods. Plot depicts the level of ant-MBP immunoglobulin isotypes in the serum of EAE (n = 9) and control (n = 6) rats treated with LOV and RLP in combination or individually as determined by ELISA-based assay described under methods (E). Data in plots are expressed as Mean ± SD from three

independent experiments. Statistical significance * p<0.05, ** p<0.01, *** p<0.001 and 'NS' (not-significant) versus EAE (VEH).

Figure 6. Protein level of pro-inflammatory and anti-inflammatory mediators in the SC of EAE rats following treatment with lovastatin and rolipram in combination or individually
Plots depict the level of IFN-γ (A), IL-17 (B), IL-4 (E) and IL-10 (F) in the SC homogenate of EAE (n = 9) and control (n = 6) rats treated with lovastatin (LOV) and rolipram (RLP) in combination or individually as determined by ELISA-based assay described under methods. Autoradiograph (C) and plot (D) depict immunoblotting of iNOS protein in the SC of EAE rats in each group. Data in plots are expressed as Mean ± SD from three independent experiments. Statistical significance * p<0.05, ** p<0.01 and 'NS' (not-significant) versus EAE (VEH).

Figure 7. Level of proteins associated with Treg cells and immunotolerance in the SC of EAE rats
Immunoblot depicts CD25, IDO, and β-actin in the SC of EAE animals treated/untreated with LOV and RLP in combination or individually (**A**). Plot depicts TGF-β1 level in the SC homogenate of EAE (n = 9) and control (n = 6) animals treated with lovastatin (LOV) and rolipram (RLP) in combination or individually as determined by ELISA-based assay described under methods (**B**). Representative photograph of the lateral funiculus of SC of EAE animals treated with LOV and RLP i.e., a) CON (VEH), b) CON (LOV + RLP), c) EAE (VEH), d) EAE (RLP), e) EAE (LOV) and f) EAE (LOV + RLP) demonstrating the expression of IDO in the SC (**C**). Data in plot is expressed as Mean ± SD from three independent experiments. Statistical significance * p<0.05, ** p<0.01 and 'NS' (not-significant) versus EAE (VEH).

Table 1

Genes and DNA sequences of primers i.e., forward primer (FP) and reverse primer (RP) used for *QRT*-PCR amplification

Gene Name	Primers
GAPDH	**FP**: 5′-cctacccccaatgtatccgttgtg-3′; **RP**: 5′-ggaggaatgggagttgctgttgaa-3′
18S rRNA	**FP**: 5′-ccagagcgaaagcatttgccaaga-3′; **RP**: 5′-tcggcatcgtttatggtcggaact-3′
IL-23	**FP**: 5′-atcaccactgggagactcaacaga-3′; **RP**: 5′-tgcgaaggatcttggaacggagaa-3′
IL-17	**FP**: 5′-actcagctgaaaacgctgaggaaa-3′; **RP**: 5′-tgtgcacaccttactgagagacct-3′
IFN-γ	**FP**: 5′-atttccctcccccactccattag-3′; **RP**: 5′-ctggtgacagctggtgaatca-3′
IL-1β	**FP**: 5′-gagagacaagcaacgacaaaatcc-3′; **RP**: 5′-ttcccatcttcttctttgggtattg-3′
TNF-α	**FP**: 5′-cttctgtctactgaacttcggggt-3′; **RP**: 5′-tggaactgatgagagggagcc-3′
iNOS	**FP**: 5′-ggaagaggaacaactactgctggt-3′; **RP**: 5′-gaactgagggtacatgctggagc-3′
IL-4	**FP**: 5′-ggtatccacggatgtaacgacagc-3′; **RP**: 5′-ccgtggtgttccttgttgccgtaa-3′
IL-10	**FP**: 5′-ctgtcatcgatttctccctgtgag-3′; **RP**: 5′-tgagtgtcgcgtaggcttctatgc-3′
TGF-β1	**FP**: 5′-tgatacgcctgagtggctgtcttt-3′; **RP**: 5′-aagcgaaagccctgtattccgtct-3′
CD4	**FP**: 5′-aggtctcccttcagtttgctggtt-3′; **RP**: 5′-tcaccaccaggttcacttcctgat-3′
CD8	**FP**: 5′-aaagcaagacctggaccaacgaga-3′; **RP**: 5′-taacgtgcctgaccattcacagga-3′
CD25	**FP**: 5′-ccaaacgcaagccaaaccaaacag-3′; **RP**: 5′-acacgaggctgacggtcaacataa-3′
Foxp3	**FP**: 5′-agagtttctcaagcactgccaagc-3′; **RP**: 5′-tgcatagctcccagcttctcctt-3′
IDO	**FP**: 5′-aagcactggagaaggcactgtgta-3′; **RP**: 5′-atccacgaagtcacgcatcctctt-3′
ICAM-1	**FP**: 5′-gtccaattcacactgaatgccagc-3′; **RP**: 5′-ttaaacaggaactttcccgccacc-3′
VCAM-1	**FP**: 5′-gacaccgtcattatctcctgcact-3′; **RP**: 5′-gtgtacgagccatccacagacttt-3′
MCP-1	**FP**: 5′-gaccagaaccaagtgagatca-3′; **RP**: 5′-gcttcagatttatgggtcaagt-3′
CCR-2	**FP**: 5′-tctacttcttctggactccataca-3′; **RP**: 5′-ctaagtgcatgtcaaccacac-3′